This mechanism is consistent with previous reports demonstrating that MAP4 overexpression promotes microtubule stabilization [9,10,11,12,13,14], enhancing the response to paclitaxel and other microtubule-stabilizing agents in breast cancer and other cancers [15,16,17]. Here, MAP4 is linked to breast cancer.